CR9652A - Moduladores de alquilquinolina y alquilquinazolina cinasa - Google Patents

Moduladores de alquilquinolina y alquilquinazolina cinasa

Info

Publication number
CR9652A
CR9652A CR9652A CR9652A CR9652A CR 9652 A CR9652 A CR 9652A CR 9652 A CR9652 A CR 9652A CR 9652 A CR9652 A CR 9652A CR 9652 A CR9652 A CR 9652A
Authority
CR
Costa Rica
Prior art keywords
compounds
kit
flt3
trkb
modulators
Prior art date
Application number
CR9652A
Other languages
English (en)
Inventor
Baindur Nand
David Gaul Michael
Douglas Kreutter Kevin
Andrew Baumann Christian
J Kim Alexander
Xu Guozhang
W Tuman Robert
L Johnson Dana
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR9652A publication Critical patent/CR9652A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invencion se refiere a compuestos alquinolina y alquinazolina de formula I: en donde R1, R2, R3, B, Z, G, Q, y X son como se define en la presente, el uso de dichos compuestos como moduladores de proteina tirosina cinasa, particularmente inhibidores de FLT3 y/o c-kit y/o TrkB, el uso de dichos compuestos para reducir o inhibir la actividad cinasa de FLT3 y/o c kit y/o TrkB en una celula o en un sujeto, y el uso de dichos compuestos para la prevencion o tratamiento en un sujeto de un trastorno proliferante celular y/o trastornos relacionados a FLT3 y/o c kit y/o TrkB; la presente invencion se refiere ademas a composiciones farmaceuticas que comprenden los compuestos de la presente invencion y a metodos para el tratamiento de condiciones tales como canceres y otros trastornos proliferantes celulares.
CR9652A 2005-06-10 2008-01-09 Moduladores de alquilquinolina y alquilquinazolina cinasa CR9652A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68938405P 2005-06-10 2005-06-10
US73091905P 2005-10-27 2005-10-27

Publications (1)

Publication Number Publication Date
CR9652A true CR9652A (es) 2008-09-09

Family

ID=37038081

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9652A CR9652A (es) 2005-06-10 2008-01-09 Moduladores de alquilquinolina y alquilquinazolina cinasa

Country Status (18)

Country Link
US (1) US8071768B2 (es)
EP (1) EP1893598A1 (es)
JP (1) JP2009501135A (es)
KR (1) KR20080028912A (es)
AR (1) AR054386A1 (es)
AU (1) AU2006257945A1 (es)
BR (1) BRPI0611964A2 (es)
CA (1) CA2611242A1 (es)
CR (1) CR9652A (es)
EA (1) EA200800017A1 (es)
EC (1) ECSP077997A (es)
GT (1) GT200600251A (es)
IL (1) IL187692A0 (es)
NO (1) NO20080174L (es)
PE (1) PE20070014A1 (es)
TW (1) TW200716599A (es)
UY (1) UY29588A1 (es)
WO (1) WO2006135721A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) * 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8760507B2 (en) * 2008-08-05 2014-06-24 Inspectron, Inc. Light pipe for imaging head of video inspection device
JPWO2011078369A1 (ja) * 2009-12-25 2013-05-09 持田製薬株式会社 新規アリールウレア誘導体
BR112013006953A2 (pt) 2010-09-29 2016-07-26 Intervet Int Bv composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
AU2012288900B2 (en) 2011-07-27 2016-10-06 Ab Science Selective protein kinase inhibitors
CA2891926A1 (en) * 2012-11-20 2014-05-30 Merial, Inc. Anthelmintic compounds and compositions and method of using thereof
BR112016008080B1 (pt) * 2013-10-16 2021-02-23 Fujifilm Corporation sal de ácido carboxílico ou um sal de ácido mineral, cristal de succinato, cristal de fumarato e composição farmacêutica
EP3083602A1 (en) * 2013-12-20 2016-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
JP6412471B2 (ja) * 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
CN110950842B (zh) * 2018-09-27 2023-06-20 深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
CA3128085A1 (en) * 2018-12-21 2020-06-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Dna-pkcs inhibitors for increasing genome editing efficiency

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517005A (en) * 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5300515A (en) * 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
DE69623455T2 (de) 1995-04-19 2003-01-16 Schneider (Usa) Inc., Plymouth Beschichteter dilatator zur abgabe eines arzneistoffs
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
JP2001511764A (ja) 1996-04-12 2001-08-14 住友製薬株式会社 ピペリジニルピリミジン誘導体
US5869669A (en) * 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
CA2239227C (en) * 1996-10-01 2007-10-30 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
US5866562A (en) * 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
EP1047691A1 (en) 1997-12-12 2000-11-02 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
EP1309569B1 (en) 2000-08-18 2010-10-06 Millennium Pharmaceuticals, Inc. N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors
EP1309567A2 (en) 2000-08-18 2003-05-14 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds
CA2424689A1 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
EP1347982B1 (en) 2000-12-12 2005-11-16 Neurogen Corporation Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
DE10109866A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
JP4310109B2 (ja) * 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
IL161156A0 (en) 2001-10-30 2004-08-31 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003057690A1 (en) 2001-12-27 2003-07-17 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
CN1625555A (zh) 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
AU2003247772A1 (en) 2002-06-27 2004-01-19 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
CA2501932C (en) 2002-11-13 2014-03-11 Chiron Corporation Use of benzimidazole quinolinones for treating cancer
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
ATE425160T1 (de) 2002-12-18 2009-03-15 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
ES2344007T3 (es) 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
US20050130954A1 (en) 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators

Also Published As

Publication number Publication date
EP1893598A1 (en) 2008-03-05
US8071768B2 (en) 2011-12-06
TW200716599A (en) 2007-05-01
AR054386A1 (es) 2007-06-20
UY29588A1 (es) 2006-10-02
CA2611242A1 (en) 2006-12-21
AU2006257945A1 (en) 2006-12-21
JP2009501135A (ja) 2009-01-15
IL187692A0 (en) 2008-08-07
GT200600251A (es) 2007-01-12
BRPI0611964A2 (pt) 2009-01-27
NO20080174L (no) 2008-02-19
WO2006135721A1 (en) 2006-12-21
ECSP077997A (es) 2008-01-23
EA200800017A1 (ru) 2008-08-29
US20060281772A1 (en) 2006-12-14
KR20080028912A (ko) 2008-04-02
PE20070014A1 (es) 2007-03-08

Similar Documents

Publication Publication Date Title
ECSP077997A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa
ECSP077994A (es) Aminopirimidinas como moduladores de cinasa
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
ECSP077991A (es) Aminopirimidinas como moduladores de cinasa
CR9650A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms
NI200800179A (es) Triazolopiridazinas como moduladores de la tirosina cinasa
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CR10094A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
ECSP109953A (es) Derivados de piridazinona
GT200600143A (es) Fenilacetamidas apropiadas como inhibidores de la proteina kinasa
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
ECSP088152A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
ECSP10010361A (es) Derivados de piridazinona
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
NI200700312A (es) Intermediarios útiles en las síntesis de moduladores de la cinasa de alquilquinoleína y alquilquinazolina y métodos de síntesis relacionados.
CR20110082A (es) Nuevos inhibidores de la proteina tirosina quinasa y receptores vegf-2 y uso farmacéutico de los mismos
EA200702136A1 (ru) Композиции станнсопорфина и их применение
UY29592A1 (es) Aminopirimidinas como moduladores de quinasas
UY29587A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
CR9238A (es) Pirrolopirazoles, potentes inhibidores de cinasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)